For the year ending 2025-12-31, RIGL had -$16,109K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Total revenues | 294,282 |
| Employee related expenses | 75,314 |
| Commercial related expenses | 25,898 |
| Cost of product sales | 19,621 |
| Consultants and third-party services | 15,146 |
| Outside clinical trial related expenses | 18,307 |
| Other segment items | 14,530 |
| Interest expense, net | -3,639 |
| (benefit from) provision for income taxes | -245,197 |
| Net income (loss) | 367,024 |
| Stock-based compensation expense | 12,711 |
| (gain) loss on sale and disposal of fixed assets | 0 |
| Depreciation and amortization | 2,415 |
| Deferred income tax benefit | -245,852 |
| Release of cost share liability | 39,981 |
| Net amortization of discount on short-term investments and term loans | 1,150 |
| Accounts receivable, net | 10,148 |
| Inventories | 5,635 |
| Prepaid and other current and non-current assets | 11,848 |
| Right-of-use assets | -674 |
| Accounts payable | 3,852 |
| Accrued compensation | 1,775 |
| Accrued research and development | 1,451 |
| Revenue reserves and refund liability | 1,276 |
| Other current and long-term liabilities | -285 |
| Lease liability | 724 |
| Net cash provided by (used in) operating activities | 75,655 |
| Maturities of short-term investments | 61,129 |
| Purchases of short-term investments | 153,494 |
| Capital expenditures | 0 |
| Payments for acquisition of intangible assets | 0 |
| Proceeds from sale of property and equipment | 0 |
| Net cash (used in) provided by investing activities | -92,365 |
| Net proceeds from term loan financing | 0 |
| Principal payments of term loans | 7,500 |
| Net proceeds from issuance of common stock from equity plans | 8,101 |
| Closing purchase price payment related to asset acquisition | 0 |
| Cost share payments to a collaboration partner | 0 |
| Net cash provided by (used in) financing activities | 601 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -16,109 |
| Cash and cash equivalents at beginning of period | 56,746 |
| Cash, cash equivalents, and restricted cash at end of period | 40,637 |
RIGEL PHARMACEUTICALS INC (RIGL)
RIGEL PHARMACEUTICALS INC (RIGL)